Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


3 Anticancer Res
1 BMC Cancer
1 BMC Urol
2 Br J Radiol
2 Cancer
1 Cancer Imaging
2 Clin Cancer Res
2 Curr Treat Options Oncol
1 Discov Oncol
2 Eur Urol
2 Int J Urol
2 J Urol
1 Nat Rev Cancer
2 Nat Rev Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

    Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications.
    Anticancer Res. 2024;44:463-470.
    PubMed         Abstract available

  2. KUROKAWA G, Mori K, Sasaki H, Nakano J, et al
    Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
    Anticancer Res. 2024;44:679-686.
    PubMed         Abstract available

  3. SAKAMOTO S, Ando K, Pae S, Zhao X, et al
    Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:639-647.
    PubMed         Abstract available

    BMC Cancer

  4. LING SW, van der Veldt AAM, Konijnenberg M, Segbers M, et al
    Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
    BMC Cancer. 2024;24:146.
    PubMed         Abstract available

    BMC Urol

  5. SIGG S, Lehner F, Keller EX, Saba K, et al
    Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer.
    BMC Urol. 2024;24:24.
    PubMed         Abstract available

    Br J Radiol

  6. CHENG T, Li H
    Prediction of Gleason score in prostate cancer patients based on radiomic features of transrectal ultrasound images.
    Br J Radiol. 2024;97:415-421.
    PubMed         Abstract available

  7. PAN K, Yao F, Hong W, Xiao J, et al
    Multimodal radiomics based on 18F-Prostate-specific membrane antigen-1007 PET/CT and multiparametric MRI for prostate cancer extracapsular extension prediction.
    Br J Radiol. 2024;97:408-414.
    PubMed         Abstract available


  8. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    PubMed         Abstract available

  9. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    PubMed         Abstract available

    Cancer Imaging

  10. MA Y, Gao F
    Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
    Cancer Imaging. 2024;24:19.
    PubMed         Abstract available

    Clin Cancer Res

  11. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    PubMed         Abstract available

  12. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    PubMed         Abstract available

    Curr Treat Options Oncol

  13. COOLEY LF, Srivastava A, Shore ND
    Updates on Management of Biochemical Recurrent Prostate Cancer.
    Curr Treat Options Oncol. 2024 Jan 3. doi: 10.1007/s11864-023-01164.
    PubMed         Abstract available

  14. SERRITELLA AV, Hussain M
    Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.
    Curr Treat Options Oncol. 2024 Jan 4. doi: 10.1007/s11864-023-01173.
    PubMed         Abstract available

    Discov Oncol

  15. SAMUEL E, Zaman S, Bakar MA, Fareed MM, et al
    Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer.
    Discov Oncol. 2024;15:27.
    PubMed         Abstract available

    Eur Urol

  16. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
    Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  17. VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
    Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
    Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

    Int J Urol

  18. SHOJI S
    Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.

  19. LIN YH, Chen YT, Tsai HY
    Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.

    J Urol

  20. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
    Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
    J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
    PubMed         Abstract available

  21. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
    Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
    J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
    PubMed         Abstract available

    Nat Rev Cancer

  22. BREWER G
    Mapping the prostate cell family tree.
    Nat Rev Cancer. 2024;24:96.

    Nat Rev Urol

  23. CARCELES-CORDON M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V, et al
    The yin and yang of chromosomal instability in prostate cancer.
    Nat Rev Urol. 2024 Feb 2. doi: 10.1038/s41585-023-00845.
    PubMed         Abstract available

  24. JOHNSON JR, Mavingire N, Woods-Burnham L, Walker M, et al
    The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men.
    Nat Rev Urol. 2024 Feb 2. doi: 10.1038/s41585-023-00849.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.